← Back to Screener
Embecta Corp. Common Stock (EMBC)
Price$9.60
Favorite Metrics
Price vs S&P 500 (26W)-35.65%
Price vs S&P 500 (4W)0.52%
Market Capitalization$579.17M
P/E Ratio (Annual)6.07x
Indicated Dividend Yield (Annual)6.13%
All Metrics
P/CF (Annual)3.02x
Book Value / Share (Quarterly)$-14.33
Indicated Dividend (Annual)$0.60
Revenue Growth (3Y)-1.47%
Cash Flow / Share (Quarterly)$3.48
Payout Ratio (TTM)25.16%
Price vs S&P 500 (YTD)-21.82%
Gross Margin (TTM)63.17%
Net Profit Margin (TTM)12.92%
EPS (TTM)$2.37
10-Day Avg Trading Volume0.62M
EPS Excl Extra (TTM)$2.37
Revenue Growth (5Y)-0.10%
EPS (Annual)$1.62
Dividend / Share (Annual)$0.60
ROI (Annual)69.87%
Gross Margin (Annual)63.86%
Net Profit Margin (5Y Avg)15.50%
Cash / Share (Quarterly)$3.40
P/E Basic Excl Extra (TTM)4.15x
Revenue Growth QoQ (YoY)-0.27%
EPS Growth (5Y)-26.19%
P/E Normalized (Annual)6.07x
ROA (Last FY)8.75%
Revenue Growth TTM (YoY)-2.53%
EBITD / Share (TTM)$5.78
Operating Margin (TTM)27.48%
Cash Flow / Share (Annual)$3.12
P/B Ratio1.05x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.64x
Net Interest Coverage (TTM)2.27x
ROA (TTM)12.59%
EV / EBITDA (TTM)5.20x
EPS Incl Extra (Annual)$1.62
Current Ratio (Annual)2.41x
Quick Ratio (Quarterly)1.55x
3-Month Avg Trading Volume0.80M
52-Week Price Return-13.76%
EV / Free Cash Flow (Annual)9.71x
P/E Incl Extra (TTM)4.15x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$-14.76
P/S Ratio (Annual)0.54x
Asset Turnover (Annual)0.99x
52-Week High$15.55
Operating Margin (5Y Avg)25.33%
EPS Excl Extra (Annual)$1.62
CapEx CAGR (5Y)-26.03%
26-Week Price Return-26.91%
Quick Ratio (Annual)1.44x
13-Week Price Return-23.29%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.64x
Enterprise Value$1,771.97
Revenue / Share Growth (5Y)-0.45%
Asset Turnover (TTM)0.97x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.23x
Pretax Margin (Annual)12.62%
Cash / Share (Annual)$3.85
3-Month Return Std Dev40.04%
Gross Margin (5Y Avg)66.70%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-11.51%
EBITDA Interim CAGR (5Y)-7.04%
ROE (Last FY)69.87%
Net Interest Coverage (Annual)2.89x
EPS Basic Excl Extra (Annual)$1.62
P/FCF (TTM)2.81x
Receivables Turnover (TTM)6.35x
EV / Free Cash Flow (TTM)8.61x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$2.37
Receivables Turnover (Annual)6.36x
ROI (TTM)8.55%
P/S Ratio (TTM)0.54x
Pretax Margin (5Y Avg)18.24%
Revenue / Share (Annual)$18.34
Tangible BV / Share (Annual)$-14.76
Forward P/E3.41x
Free OCF CAGR (5Y)-16.78%
Price vs S&P 500 (52W)-48.85%
P/E Ratio (TTM)4.15x
EPS Growth TTM (YoY)134.75%
Year-to-Date Return-17.68%
5-Day Price Return5.62%
EPS Normalized (Annual)$1.62
ROA (5Y Avg)18.78%
Net Profit Margin (Annual)8.83%
Month-to-Date Return10.63%
Cash Flow / Share (TTM)$1.79
EBITD / Share (Annual)$4.83
EPS Growth (3Y)-25.33%
Operating Margin (Annual)22.41%
P/CF (TTM)2.70x
P/E Excl Extra (TTM)4.15x
EPS Basic Excl Extra (TTM)$2.37
Payout Ratio (Annual)36.69%
Dividend / Share (TTM)$0.60
Inventory Turnover (TTM)2.27x
Pretax Margin (TTM)18.14%
Book Value / Share (Annual)$-14.33
Price vs S&P 500 (13W)-26.16%
Net Margin Growth (5Y)-25.86%
Dividend Yield (TTM)6.06%
Beta1.18x
P/FCF (Annual)3.18x
Revenue / Share (TTM)$18.21
ROE (TTM)6.12%
52-Week Low$8.47
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.56
2.56
2.56
2.56
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
EMBCEmbecta Corp. Common Stock | 0.54x | -0.10% | 63.17% | 27.48% | $9.60 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Embecta Corp manufactures diabetes care products including insulin pen needles, syringes, and safety devices sold through wholesalers and distributors, with the majority of revenue from the United States. The company also offers a proprietary digital application for diabetes management and provides contract manufacturing services.